A Study to Assess Menstrual Cramp Pain Associated With Primary Dysmenorrhea

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

201 participants

Study Classification

INTERVENTIONAL

Study Start Date

2018-04-05

Study Completion Date

2018-09-05

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to compare the maximum single dose of Aleve® (two tablets, equivalent to 440 mg of naproxen sodium) to the maximum single dose of Tylenol Extra Strength (two caplets, equivalent to 1000 mg of acetaminophen) in the treatment of menstrual pain associated with primary dysmenorrhea.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Non-Steroidal Anti-Inflammatory Drug (NSAID) Response and Central Sensitization of Pain in Women With Dysmenorrhea

NCT05900336

Dysmenorrhea Menstrual Pain Non-steroidal Anti-inflammatory Drug

COMPLETED PHASE4

Efficacy and Safety, Long-Term Study of NPC-16 to Treat Dysmenorrhea

NCT02362711

Dysmenorrhea

COMPLETED PHASE3

Efficacy and Safety Study of NPC-01 to Treat Dysmenorrhea

NCT01129102

Dysmenorrhea

COMPLETED PHASE3

Effectiveness of PEA Compared to Placebo on Acute Menstrual Pain

NCT05810116

Menstrual Pain

COMPLETED PHASE4

A Study of Acetaminophen/Naproxen Sodium Fixed Combination Tablets in Adolescents 12 to <17 Years of Age With Pain

NCT05844995

Orthodontic Pain

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Dysmenorrhea

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Naproxen Sodium : Acetaminophen

Subjects received one single oral dose of 440 mg naproxen sodium in treatment period 1, followed by one single oral dose of 1000 mg acetaminophen in treatment period 2

Group Type EXPERIMENTAL

Naproxen Sodium, (Aleve, BAY117031)

Intervention Type DRUG

220 mg \*2 tablets, orally, single dose

Acetaminophen (Tylenol Extra Strength)

Intervention Type DRUG

500 mg \*2 caplets, orally, single dose

Acetaminophen : Naproxen Sodium

Subjects received one single oral dose of 1000 mg acetaminophen in treatment period 1, followed by one single oral dose of 440 mg naproxen sodium in treatment period 2

Group Type EXPERIMENTAL

Naproxen Sodium, (Aleve, BAY117031)

Intervention Type DRUG

220 mg \*2 tablets, orally, single dose

Acetaminophen (Tylenol Extra Strength)

Intervention Type DRUG

500 mg \*2 caplets, orally, single dose

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Naproxen Sodium, (Aleve, BAY117031)

220 mg \*2 tablets, orally, single dose

Intervention Type DRUG

Acetaminophen (Tylenol Extra Strength)

500 mg \*2 caplets, orally, single dose

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Ambulatory healthy female patients between 15 and 35 years of age;
* Patient has a history of Over-the-Counter (OTC) analgesic use for treatment of primary dysmenorrhea;
* Patient has a history of regular menstrual cycles that typically occurs between every 21 to 35 days;
* Patient has a self-reported history of primary dysmenorrhea (onset \<5 years after menarche) with at least moderate menstrual cramp pain (based on the categorical pain intensity scale, 0-3) occurring during four of the past six menstrual cycles;
* Patient has a self-reported history of primary dysmenorrhea with other causes of dysmenorrhea having been excluded;
* Patient typically requires at least one dose of an OTC analgesic medication such as naproxen, aspirin, acetaminophen, or ibuprofen taken on at least 1 day of her menstrual cycle for the treatment of moderate or severe menstrual cramp, and normally experiences pain relief from these medications;
* Patient is of child-bearing potential and is using one of the following methods of contraception and agrees to continue this same method for the duration of the study:

* Abstinence for at least the last 60 days AND willingness to use double barrier method should the patient become sexually active during the study;
* Double barrier method (condom with contraceptive foam, diaphragm with contraceptive gel);
* Permanent sterilization of patient or her spouse/partner;
* Oral contraceptive (must have been using the same oral contraceptive for at least three months prior to study entry and agrees to remain on the same type and method throughout the course of the study).
* Patient is willing to participate in the study and return to the study site within approximately 1 week after her menstrual cycle to return the study medication, urine pregnancy test, and for review of the completed patient e-diary;
* Patient is willing to abstain from alcohol consumption throughout the 12-hour Treatment Period;
* Patient is willing to abstain from caffeine consumption throughout the 12-hour Treatment Period;
* Patient is willing to ingest the overencapsulated tablets throughout the study;
* Patient is willing and able to participate in all scheduled visits, treatment plan, laboratory tests and other study procedures according to the clinical protocol.

Exclusion Criteria

* Patient has a known history of allergic, idiosyncratic or serious adverse reaction, to acetaminophen, naproxen, aspirin, ibuprofen, or any other nonsteroidal anti-inflammatory drug (NSAID);
* Patient has a known allergy to any of the excipients in any of the study medication products;
* Patient has experienced asthma, urticaria, or allergic-type reactions after taking aspirin, acetaminophen or other NSAIDs;
* Patient has significant co-existing illness, including gastrointestinal, hepatic, renal, neurologic, cardiovascular, psychiatric, endocrine, respiratory, surgical procedure or other condition that, in the Investigator's judgment, contraindicates administration of the study medication;
* Patient has a current or past history of severe gastritis, gastrointestinal bleeding or ulceration;
* Patient has a current or past history of one or more of the following conditions: secondary dysmenorrhea, pelvic inflammatory disease, urinary tract infection (currently acute or recurrent \[defined as more than three per year\] prior history of an urinary tract infection is eligible for enrollment), adnexal masses, uterine fibroids, endometriosis, adenomyosis that in the opinion of the Investigator would impact patient safety and/or the study data;
* Patient has an ongoing sexually transmitted disease (except for a history of genital herpes or Human Papillomavirus) or has abnormal vaginal discharge;
* Patient requires prescription analgesics, narcotic, non-NSAID (i.e., defined as oral use of 5 or more times per week for greater than 3 weeks) or has routinely taken OTC medications in excess of label recommended instructions for control of dysmenorrhea symptoms;
* Patient is taking mood-altering agents (e.g., antidepressants, sedatives, phenothiazines, or anti-anxiety agents). Patients who are on a stable dose for at least 3 months, and not taking this medication for dysmenorrhea or premenstrual syndrome are eligible for enrollment;
* Patient does not agree to abstain from taking any analgesic and/or anti-inflammatory medication (with the exception of low dose aspirin \[defined as no greater than 100 mg daily\] taken for cardioprotective purposes) approximately 72 hours prior to the anticipated treatment period and throughout the dosing/assessment period. All pain and anti-inflammatory medications including supplements, topical heat or cold, and other products of topical application will be discontinued approximately 72 hours prior to the anticipated dosing for each treatment period and throughout the dosing/assessment period;
* Patient does not agree to abstain from using transcutaneous electrical nerve stimulation devices that are used to treat dysmenorrhea throughout each treatment period;
* Patient is taking piroxicam (Feldene®) or oral corticosteroids. Patients taking inhaled or topical corticosteroids are eligible for enrollment;
* Patient is pregnant, lactating , or less than 6 months postpartum;
* Patient is currently using an intra-uterine devices (IUD), or using hormonal implants (e.g., Norplant) or injections (e.g., Depo-Provera) for contraception or used within the past 6 months;
* Patient is currently using an oral contraceptive for less than 3 months, has been on a unstable dose within the last 3 months or has switched from one oral contraceptive to another within the last 3 months or intends to do so in the course of the study;
* Patient has a history of chronic abuse of alcohol (regularly consumes 3 or more alcoholic drinks per day), analgesics, narcotic analgesics, ergot alkaloids, tranquilizers, or opioids or other substances known to produce dependence; in the judgement of the investigator within the past 3 years;
* Positive drug at screening and visit 2 for illegal drug substances, or non-prescribed controlled substances;
* Positive pregnancy test or breast feeding at screening and prior to dosing in each Treatment Period;
* Patients with a medical disorder, condition or history such that could impair the patient's ability to participate or complete this study in the opinion of the investigator.

Minimum Eligible Age

15 Years

Maximum Eligible Age

35 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No